These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1090 related articles for article (PubMed ID: 26601866)

  • 1. Targeted Therapy for Melanoma.
    Wong DJ; Ribas A
    Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P; Picasso V; Spagnolo F
    Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies for cutaneous melanoma.
    Kee D; McArthur G
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A; Tsai K
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
    Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
    Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF and MEK inhibition in melanoma.
    Dossett LA; Kudchadkar RR; Zager JS
    Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.
    Roukos DH; Papaloukas C; Tzaphlidou M
    Future Oncol; 2013 Jan; 9(1):5-8. PubMed ID: 23252557
    [No Abstract]   [Full Text] [Related]  

  • 12. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achievements and challenges of molecular targeted therapy in melanoma.
    Sullivan R; LoRusso P; Boerner S; Dummer R
    Am Soc Clin Oncol Educ Book; 2015; ():177-86. PubMed ID: 25993155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK; Kim KB
    Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
    Jang S; Atkins MB
    Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma.
    Consoli F; Bersanelli M; Perego G; Grisanti S; Merelli B; Berruti A; Petrelli F
    Clin Transl Oncol; 2020 Jun; 22(6):900-907. PubMed ID: 31555967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors.
    Wahid M; Jawed A; Mandal RK; Dar SA; Akhter N; Somvanshi P; Khan F; Lohani M; Areeshi MY; Haque S
    Crit Rev Oncol Hematol; 2018 May; 125():84-88. PubMed ID: 29650281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.